A clinical trial to continue to provide treatments to participants who benefitted from them in an atezolizumab-based trial sponsored by Genentech Inc. and/or F. Hoffmann-La Roche Ltd

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

  • Cancer
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:

Recruiting

This study runs in
Cities
  • Aichi
  • Alvarado
  • Angers
  • Arkhangelsk
  • Athina
  • Aurora
  • Baltimore
  • Bangkok
  • Barcelona
  • Bethlehem
  • Bordeaux
  • Boston
  • Bratislavský kraj
  • Brno
  • Brussel
  • Bruxelles
  • Brzozów
  • Budapest
  • Bydgoszcz
  • Bytom
  • Charlotte
  • Chicago
  • Chihuahua
  • Cluj-Napoca
  • Craiova
  • Darlinghurst
  • Essen
  • Fort Wayne
  • Freiburg
  • Fribourg
  • Fukuoka
  • Gauting
  • Gera
  • Goiania
  • Hamburg
  • Heidelberg
  • Hokkaido
  • Hong Kong
  • Houston
  • Huntersville
  • Iasi
  • Ibaraki
  • Immenhausen
  • Ishikawa
  • Ivanovo
  • Kanagawa
  • Kharkiv
  • Kiev
  • Kryvyi Rih
  • København Ø
  • Leuven
  • Lille
  • London
  • Los Angeles
  • Lutsk
  • Lyon
  • Madrid
  • Marseille
  • Matsuyama
  • Milano
  • Moscow
  • Málaga
  • Münster
  • Nashville
  • Nice
  • Niigata
  • Okayama
  • Olomouc
  • Olsztyn
  • Osaka
  • Otwock
  • Pamplona iruña
  • Plovdiv
  • pozna-
  • Putzu
  • Pécs
  • Regensburg
  • Riga
  • Rio de Janeiro
  • Saint-Mandé
  • Saint-Petersburg
  • Saitama
  • Sakai-shi
  • San Antonio
  • Santiago
  • Scottsdale
  • Seattle
  • Seoul
  • Singapore
  • Sumy
  • Szeged
  • Székesfehérvár
  • São Paulo
  • Taichung
  • Taipei City
  • Timisoara
  • Toronto
  • Toulouse
  • Townsville
  • Trumbull
  • Tübingen
  • Ulm
  • Uzhhorod
  • València
  • Vancouver
  • Villejuif
  • Vinnytsia
  • Warszawa
  • Washington
  • Winter Park
Trial Identifier:

NCT03768063 2023-506184-34-00 BO40729

  • Advent Health Orlando

    Recruiting

    601 E Rollins St32789Winter ParkUnited States
  • Centrum Onkologii im. Prof. F. Lukaszczyka w Bydgoszczy

    Recruiting

    85-796BydgoszczPoland
  • Faculty of Med. Siriraj Hosp.

    Recruiting

    2 Thanon Wang Lang10700BangkokThailand
  • Hokkaido University Hospital

    Recruiting

    060-8648HokkaidoJapan
  • Kyushu University Hospital

    Recruiting

    812-8582FukuokaJapan
  • Nagoya University Hospital

    Recruiting

    466-8560AichiJapan
  • NHO Kinki-Chuo Chest Medical Center

    Recruiting

    591-8555Sakai-shiJapan
  • Okayama University Hospital

    Recruiting

    700-8558OkayamaJapan
  • Osaka Habikino Medical Center

    Recruiting

    583-8588OsakaJapan
  • P.A. Herzen Oncological Inst.

    Recruiting

    125248
  • Sendai Kousei Hospital

    Recruiting

    981-0914
  • Universitaettsklinikum Tübingen

    Recruiting

    72076TübingenGermany
  • Universitätsklinikum Ulm

    Recruiting

    23 Albert-Einstein-Allee89081UlmGermany
  • University of Tsukuba Hospital

    Recruiting

    305-8576IbarakiJapan
  • Uniwersytecki Szpital Kliniczny w Poznaniu

    Recruiting

    49 Przybyszewskiego60-569pozna-Poland
  • Asklepios-Fachklinik Muenchen-Gauting

    Active, not recruiting

    2 Robert-Koch-Allee82131GautingGermany
  • BAG Prof Dr G Hoheisel Dr A Bonitz

    Active, not recruiting

    4275
  • Carolina BioOncology Institute, PLCC

    Active, not recruiting

    9801 Kincey Ave28078HuntersvilleUnited States
  • Centre Antoine Lacassagne

    Active, not recruiting

    33 Av. de Valombrose06189NiceFrance
  • Centrul de Oncologie Oncohelp

    Active, not recruiting

    300239TimisoaraRomania
  • Centrul de Oncologie Sfantul Nectarie

    Active, not recruiting

    109 Strada Caracal200347CraiovaRomania
  • CHU Angers

    Active, not recruiting

    4 Rue Larrey49933AngersFrance
  • CHU Timone

    Active, not recruiting

    13005MarseilleFrance
  • Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Klinika Onkologii

    Active, not recruiting

    14/18 Borowa05-400OtwockPoland
  • Grupo Angeles

    Active, not recruiting

    01015AlvaradoGuatemala
  • HM Sanchinarro ? CIOCC

    Active, not recruiting

    10 C. de Oña28050MadridSpain
  • HOPA MVZ GmbH

    Active, not recruiting

    47 Mörkenstraße22767HamburgGermany
  • Hospital Araujo Jorge

    Active, not recruiting

    206 R. 23974605-070GoianiaBrazil
  • Hospital Universitario Quiron Dexeus

    Active, not recruiting

    08028BarcelonaSpain
  • Institut Gustave Roussy

    Active, not recruiting

    94805VillejuifFrance
  • Institutul Regional de Oncologie Iasi

    Active, not recruiting

    2-4 Strada General Henri Mathias Berthelot700483IasiRomania
  • Kanazawa University Hospital

    Active, not recruiting

    920-8641IshikawaJapan
  • Kliniken Essen-Mitte

    Active, not recruiting

    92 Henricistraße45136EssenGermany
  • Krankenhaus Barmherzige Bruder Regensburg

    Active, not recruiting

    86 Prüfeninger Str.93049RegensburgGermany
  • Lungenfachklinik Immenhausen

    Active, not recruiting

    3 Robert-Koch-Straße34376ImmenhausenGermany
  • Masaryk?v onkologický ústav

    Active, not recruiting

    656 53BrnoCzechia
  • Massachusetts General Hospital

    Active, not recruiting

    55 Fruit St02114BostonUnited States
  • Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy

    Active, not recruiting

    83/91 Reymonta05-400OtwockPoland
  • Metropolitan Hospital

    Active, not recruiting

    9 Ethnarchou Makariou185 47AthinaGreece
  • Narodowy Instytut Onkologii im. Marii Sk?odowskiej-Curie - Pa?stwowy Instytut Badawczy

    Active, not recruiting

    5 Wilhelma Konrada Roentgena02-781WarszawaPoland
  • National Hospital Organization Kyushu Medical Center

    Active, not recruiting

    810-8563FukuokaJapan
  • National Hospital Organization Shikoku Cancer Center

    Active, not recruiting

    791-0280MatsuyamaJapan
  • Niigata University Medical & Dental Hospital

    Active, not recruiting

    951-8520NiigataJapan
  • Orszagos Onkologiai Intezet

    Active, not recruiting

    7-9 Ráth György u.1122BudapestHungary
  • Pontificia Universidad Catolica de Chile

    Active, not recruiting

    367 Marcoleta8330032SantiagoChile
  • Seoul National University College of Medicine, Liver Research Institute

    Active, not recruiting

    110-460
  • Seoul National University Hospital

    Active, not recruiting

    03080SeoulKorea, Republic of
  • Szpital Specjalistyczny Podkarpacki O?rodek Onkologiczny

    Active, not recruiting

    31 Piastowa36-200BrzozówPoland
  • Universitaetsklinikum Muenster

    Active, not recruiting

    1 Albert-Schweitzer-Campus48149MünsterGermany
  • Universitätsklinik Tübingen

    Active, not recruiting

    5 Silcherstraße72076TübingenGermany
  • Universitätsklinikum Freiburg

    Active, not recruiting

    55 Hugstetter Str.79106FreiburgGermany
  • Universitätsklinikum Heidelberg

    Active, not recruiting

    672 Im Neuenheimer Feld69120HeidelbergGermany
  • University Hospital Bratislava

    Active, not recruiting

    826 06Bratislavský krajSlovakia
  • University of Colorado Cancer Center

    Active, not recruiting

    1665 Aurora Ct80045AuroraUnited States
  • University of Texas Health Sciences Center in San Antonio

    Active, not recruiting

    78229San AntonioUnited States
  • Uniwersytecki Szpital Kliniczny w Poznaniu

    Active, not recruiting

    16/18 Grunwaldzka60-780
  • UZ Brussel

    Active, not recruiting

    101 Av. du Laerbeek1090BrusselBelgium
  • UZ Leuven

    Active, not recruiting

    49 Herestraat3000LeuvenBelgium
  • Volyn Regional Oncology Dispensary

    Active, not recruiting

    43018LutskUkraine
  • Yale University School Of Medicine

    Active, not recruiting

    06611TrumbullUnited States
  • Anticancer Hospital Ag. Savas

    Completed

    171 Leof. Alexandras11522AthinaGreece
  • Arkhangelsk Regional Clinical Oncology Dispensary

    Completed

    163045ArkhangelskRussian Federation
  • Asan Medical Center

    Completed

    138-736SeoulKorea, Republic of
  • Asan Medical Center, Uni Ulsan Collegemedicine

    Completed

    138-736SeoulKorea, Republic of
  • Barts Cancer Institute

    Completed

    E1 2ATLondonUnited Kingdom
  • BC Cancer ? Vancouver

    Completed

    600 W 10th AveV5Z 4E6VancouverCanada
  • Beth Israel Deaconess Medical Center

    Completed

    330 Brookline Ave02215BostonUnited States
  • Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez

    Completed

    59037LilleFrance
  • Centre Leon Berard

    Completed

    28 Rue Laënnec69008LyonFrance
  • Centro Medico Dalinde

    Completed

    26 Tuxpan06700ChihuahuaMexico
  • Chang Gung Memorial Hospital Chiayi

    Completed

    8號 嘉朴路西段613PutzuTaiwan
  • Clinica Universidad de Navarra-Madrid

    Completed

    1 C. del Marquesado de Sta. Marta28027MadridSpain
  • Communal Non profit Enterprise Regional Center of Oncology

    Completed

    61070KharkivUkraine
  • Dana Farber Cancer Institute

    Completed

    440 Brookline Ave02215BostonUnited States
  • Fakultni nemocnice Olomouc

    Completed

    248/7 Zdravotníků779 00OlomoucCzechia
  • Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz

    Completed

    8001SzékesfehérvárHungary
  • Fort Wayne Medical Oncology and Hematology, Inc

    Completed

    7910 W Jefferson Blvd46845Fort WayneUnited States
  • HonorHealth Research Institute - Pima - Virginia G. Piper Cancer Care Network

    Completed

    10460 N 92nd St85258ScottsdaleUnited States
  • Hopital d'Instruction des Armees de Begin

    Completed

    69 Av. de Paris94160Saint-MandéFrance
  • Hospital Clinic de Barcelona

    Completed

    170 Carrer de Villarroel08036BarcelonaSpain
  • Hospital das Clinicas - UFRGS

    Completed

    297 Av. Protásio Alves90410-000
  • Hospital Regional Universitario Carlos Haya

    Completed

    86 Av. de Carlos Haya29010MálagaSpain
  • Institut Bergonie

    Completed

    33076BordeauxFrance
  • Institut Claudius Regaud

    Completed

    20-24 Rue du Pont Saint-Pierre31059ToulouseFrance
  • Institut Jules Bordet

    Completed

    90 Rue Meylemeersch1000BruxellesBelgium
  • Instituto do Cancer do Estado de Sao Paulo - ICESP

    Completed

    251 Av. Dr. Arnaldo01246-000São PauloBrazil
  • Instituto Nacional de Cancer - INCa

    Completed

    1-376 R. Visc. de Santa Isabel20560-120Rio de JaneiroBrazil
  • Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca

    Completed

    34-36 Str. Republicii400015Cluj-NapocaRomania
  • Istituto Nazionale dei Tumori

    Completed

    1 Via Giacomo Venezian20133MilanoItaly
  • Iwate Medical University Hospital

    Completed

    028-3695
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Completed

    401 N Broadway21287BaltimoreUnited States
  • Kitasato University Hospital

    Completed

    252-0375KanagawaJapan
  • Koo Foundation Sun Yat-Sen Cancer Center

    Completed

    125號 Lide Rd112Taipei CityTaiwan
  • Laiko General Hospital Athen

    Completed

    17 Agiou Thoma115 27AthinaGreece
  • Levine Cancer Institute-Carolinas Medical Center

    Completed

    1021 Morehead Medical Dr28204CharlotteUnited States
  • ME Kryviy Rih Oncology Dispensary of Dnipropetrovs?k Regional Council

    Completed

    41 Dniprovske shose St50048Kryvyi RihUkraine
  • Medstar Georgetown University Hospital

    Completed

    3800 Reservoir Rd NW20007WashingtonUnited States
  • Multiprofile Hospital for Active Treatment Central Onco Hospital OOD

    Completed

    4004PlovdivBulgaria
  • Narodny Onkologicky Ustav

    Completed

    1 Klenová833 10Bratislavský krajSlovakia
  • National Cancer Institute MOH of Ukraine

    Completed

    36022KievUkraine
  • National University Hospital

    Completed

    5 Lower Kent Ridge Rd119074SingaporeSingapore
  • Országos Onkológiai Intézet

    Completed

    7-9 Ráth György u.1122BudapestHungary
  • Pecsi Tudomanyegyetem AOK

    Completed

    12 Szigeti út7632PécsHungary
  • Phylasis Clinicas Research S de RL de CV

    Completed

    855 Blvd. Isidro Fabela50090
  • Princess Margaret Cancer Center

    Completed

    610 University AveM5G 1Z5TorontoCanada
  • Queen Mary Hospital

    Completed

    Hong KongHong Kong
  • Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary

    Completed

    40022SumyUkraine
  • Riga's East Hosp Latvian Oncol

    Completed

    LV-1079RigaLatvia
  • Russian Oncology Research Center n.a. N.N. Blokhin

    Completed

    115478MoscowRussian Federation
  • Saitama Cancer Center

    Completed

    362-0806SaitamaJapan
  • Samsung Medical Center

    Completed

    6351SeoulKorea, Republic of
  • SCRI Oncology Partners

    Completed

    335 24th Ave N37203NashvilleUnited States
  • Severance Hospital

    Completed

    03722SeoulKorea, Republic of
  • SRH Wald-Klinikum Gera

    Completed

    122 Str. des Friedens07548GeraGermany
  • St Vincent'S Hospital

    Completed

    390 Victoria St2010DarlinghurstAustralia
  • St. Luke's Cancer Care Associates

    Completed

    701 Ostrum St18015BethlehemUnited States
  • Szegedi Tudományegyetem

    Completed

    13 Dugonics tér6720SzegedHungary
  • Taichung Veterans General Hospital

    Completed

    1650號 台灣大道四段40705TaichungTaiwan
  • The University of Texas MD Anderson Cancer Center

    Completed

    77030-4009HoustonUnited States
  • Townsville Hospital

    Completed

    100 Angus Smith Dr4810TownsvilleAustralia
  • UCLA Hematology / Oncology Clinic

    Completed

    90095Los AngelesUnited States
  • Universitaets-Hautklinik Tuebingen

    Completed

    25 Liebermeisterstraße72076TübingenGermany
  • University of Washington - Seattle Cancer Care Alliance

    Completed

    820 Yale Ave N98109SeattleUnited States
  • Clínica Universidad de Navarra

    Withdrawn

    36 Av. de Pío XII31008Pamplona iruñaSpain
  • Corporacio Sanitaria Parc Tauli

    Withdrawn

    1 Parc Taulí08208
  • FBI "Scientific Research Institute of Oncology n. a. N. N. Petrov"

    Withdrawn

    197758Saint-PetersburgRussian Federation
  • Freiburger Spital

    Withdrawn

    1708FribourgSwitzerland
  • Hospital Clínico Universitario de Valencia

    Withdrawn

    17 Av. de Blasco Ibáñez46010ValènciaSpain
  • Ivanovo Regional Oncology Dispensary

    Withdrawn

    153013IvanovoRussian Federation
  • Municipal Institution Podilskiy Regional Center of Oncology

    Withdrawn

    21029VinnytsiaUkraine
  • Niigata University Medical & Dental Hospital

    Withdrawn

    951-8520NiigataJapan
  • Rigshospitalet

    Terminated

    2100København ØDenmark
  • SP ZOZ Wojewódzki Szpital Specjalistyczny nr 4

    Withdrawn

    10 al. Legionów41-902BytomPoland
  • Szpital Grochowski im. dr med. Rafa?a Masztaka Sp. z o.o.

    Withdrawn

    51/59 Grenadierów04-073WarszawaPoland
  • University Of Chicago Medical Center

    Withdrawn

    5841 S Maryland Ave60637ChicagoUnited States
  • Uzhhorod Central City Clinical Hospital

    Withdrawn

    88000UzhhorodUkraine
  • Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie

    Withdrawn

    78 Jagiellońska10-357OlsztynPoland
    Show study locations

    The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

    The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

    Results Disclaimer

    Study Summary

    This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or combination/comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study.

    Hoffmann-La Roche Sponsor
    Phase 3 Phase
    NCT03768063, BO40729, 2023-506184-34-00 Study Identifier
    All Gender
    ≥18 Years Age
    No Healthy Volunteers

    1. Why is the IMbrella B clinical trial needed?

    This clinical trial aims to provide continued clinical trial treatments to people with cancer who take part in an atezolizumab-based trial that is sponsored by Genentech, Inc. and/or F. Hoffmann-La Roche Ltd (called parent trial) and who do not have access to the treatment locally.

    People with cancer who benefit from treatment given in a clinical trial (meaning that their cancer shrinks or does not get worse) may continue to be given that treatment if there is no alternative treatment option and it is safe to do so, even if it is not approved by their health authority (such as the Food and Drug Administration (FDA), in the United States, or the European Medicines Agency (EMA). They may also continue to receive the treatment after it is approved if their health insurance or other costs would prevent them from being able to have it.

    2. How does the IMbrella B clinical trial work?

    People can take part in this trial if they have cancer and were previously treated in an atezolizumab-based clinical trial sponsored by Genentech Inc. and/or F. Hoffmann-La Roche Ltd (called the ‘parent trial’), and their cancer did not get worse when the parent trial closed.

    People who take part in this clinical trial (participants) will be given the same clinical trial treatment as in the parent trial for as long as it can help them or until they have unacceptable side effects or the trial stops. This allows patients who benefit to continue taking a clinical trial treatment that is otherwise not available to them. The clinical trial doctor will see them regularly. These clinic visits will include checks to see how the participant responds to the treatment and any side effects they may have and will be the same as, or like, the checks that were done in the parent trial. The total time of participation in the clinical trial will depend on how the participant continues to respond to treatment, the local availability of the treatment and if the trial is stopped. Participants can stop trial treatment and leave the clinical trial at any time.

    3. What are the main endpoints of the IMbrella B clinical trial?

    Since the purpose of this clinical trial is to provide continued clinical trial treatments – there is no main endpoint (the main result measured in a trial) for this trial. The clinical trial team will continue to monitor the safety of treatments – by checking the number and type of serious side effects and other certain side effects such as liver, kidney, heart, eye and immune problems. The number of treatments the participants receive in this trial will also be measured.

    4. Who can take part in this clinical trial?

    People can take part in this trial if they have cancer and have benefitted from the clinical trial treatment given in the parent trial. People may not be able to take part in this trial if they have stopped the clinical trial treatment in the parent trial for more than a certain amount of time or if they have been given certain other treatments for cancer since treatment in the parent trial stopped. People will also not be able to take part if the clinical trial treatment caused serious side effects that have not gone away or if the clinical trial treatment becomes available to them through routine healthcare outside of a clinical trial, if they are pregnant or breastfeeding, or are planning to become pregnant during the trial.

    5. What treatment will participants be given in this clinical trial?

    Everyone who joins this clinical trial will continue to be given the clinical trial treatment they received previously in a Genentech, Inc. and/or F. Hoffmann-La Roche Ltd-sponsored parent clinical trial. The treatment will be given in the same way as in the parent trial (for example, as an injection under the skin, an infusion into the vein, or as a tablet to be swallowed). This is an open-label trial, which means everyone involved, including the participant and the clinical trial doctor, will know the clinical trial treatment the participant has been given.

    6. Are there any risks or benefits in taking part in this clinical trial?

    The safety or effectiveness of the experimental treatment or use may not be fully known at the time of the trial. Most trials involve some risks to the participant. However, it may not be greater than the risks related to routine medical care or the natural progression of the health condition. People who would like to participate will be told about any risks and benefits of taking part in the clinical trial, as well as any additional procedures, tests, or assessments they will be asked to undergo. All of these will be described in an informed consent document (a document that provides people with the information they need to decide to volunteer for the clinical trial).

    Risks associated with the clinical trial treatments

    Participants may have side effects (an unwanted effect of a drug or medical treatment) from the treatments used in this clinical trial. Side effects can be mild to severe, even life-threatening, and vary from person to person. Participants will be closely monitored during the clinical trial; safety assessments will be performed regularly.

    Participants will be told about the known side effects of clinical trial treatments and possible side effects based on human and laboratory studies or knowledge of similar drugs. Participants will be told about any known side effects of how the treatment will be given – for example, injections under the skin (subcutaneous injections), infusions into a vein (intravenous infusions), or swallowing tablets.

    Potential benefits associated with the clinical trial

    Participants' health may or may not improve from participation in the clinical trial. Still, the information collected may help other people with similar medical conditions in the future.

    Study Summary

    This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or combination/comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study.

    Hoffmann-La Roche Sponsor
    Phase 3 Phase
    NCT03768063, BO40729, 2023-506184-34-00 Trial Identifier
    Atezolizumab, Bevacizumab, Alectinib, Cobimetinib, Vemurafenib, FAP IL2V, Venetoclax, Enzalutamide, Pembrolizumab, Sunitinib, Niraparib, Cabozantinib, Pemetrexed, Paclitaxel, Emactuzumab, Rucaparib Treatments
    Cancer Condition
    Official Title

    An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)

    Eligibility Criteria

    All Gender
    ≥18 Years Age
    No Healthy Volunteers
    Inclusion Criteria
    • Eligible for continuing atezolizumab-based therapy at the time of roll-over from the parent study, as per the parent study protocol or
    • Eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored study as per the parent study protocol, with no access to commercially available comparator agent
    • Time between the last dose of treatment received in parent study and first dose in extension study is no longer than the interruption period allowed in the parent study. First dose of study treatment in this extension study will be received within 7 days of the treatment interruption window allowed by the parent study
    • Continue to benefit from atezolizumab-based study treatment or from the comparator at the time of roll-over from the parent study as assessed by the investigator
    • Negative serum pregnancy test within 7 days prior to start of study treatment in women of childbearing potential
    • For women of childbearing potential: agreement to remain abstinent or use contraceptive methods, and agreement to refrain from donating eggs
    • For men: agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating sperm
    Exclusion Criteria
    • Meet any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in this extension study
    • Study treatment or comparator agent is commercially marketed in the patient's country for the patient-specific disease and is accessible to the patient
    • Treatment with any anti-cancer treatment during the time between last treatment in the parent study and the first dose of study treatment in this extension study
    • Permanent discontinuation of atezolizumab for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this extension study (if applicable). Exception: Participants who permanently discontinued atezolizumab from parent studies that permit participants to continue treatment with the combination agent(s) alone after permanently discontinuing atezolizumab are eligible to enroll in this study.
    • Ongoing serious adverse event(s) that has not resolved to baseline level or Grade ≤1 from the parent study or during the time between the last treatment in the parent study and the first dose of study treatment in this extension study
    • Any condition that, in the opinion of the investigator, would interfere with the interpretation of patient safety or place the patient at high risk for treatment-related complications
    • Concurrent participation in any therapeutic clinical trial (other than the parent study)
    • Pregnant or lactating, or intending to become pregnant during this extension study and for the period after the last dose of study treatment specified in the designated referenced safety information (RSI)

    About Clinical Research

    What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

    Find out now